Three Korean firms’ March sales up 20 percent

Published: 2009-04-20 06:56:00

Updated: 2009-04-20 06:56:00

The domestic industry’s top players - Dong-A Pharm, Yuhan Corporation and Chong Kun Dang Pharm – saw a steep hike in March sales on the back of their generic releases, according to market analysts.

Boosted by robust sales of flagship products such as Stillen and Opalmon, Dong-A recorded 36.4 p...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK